Insider Transactions in Q4 2023 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
17,135
-13.62%
|
$6,973,945
$407.0 P/Share
|
|
Dec 15
2023
|
Reshma Kewalramani CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
17,135
+6.36%
|
$2,930,085
$171.55 P/Share
|
|
Dec 13
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
13,354
-30.1%
|
$5,328,246
$399.8 P/Share
|
|
Dec 13
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
8,603
-13.2%
|
$3,432,597
$399.0 P/Share
|
|
Dec 13
2023
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,603
+11.66%
|
$1,608,761
$187.53 P/Share
|
|
Dec 13
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
5,098
-4.48%
|
$2,023,906
$397.0 P/Share
|
|
Dec 05
2023
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,136
+50.0%
|
-
|
|
Nov 20
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.04%
|
$1,047,000
$349.88 P/Share
|
|
Nov 15
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
35
-0.06%
|
$12,915
$369.92 P/Share
|
|
Nov 15
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
19
-0.06%
|
$7,011
$369.92 P/Share
|
|
Nov 14
2023
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
5,650
-16.17%
|
$2,147,000
$380.82 P/Share
|
|
Nov 13
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
5,097
-4.29%
|
$1,921,569
$377.0 P/Share
|
|
Nov 06
2023
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
11,250
-21.95%
|
$4,331,250
$385.0 P/Share
|
|
Nov 06
2023
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+18.0%
|
$1,428,750
$127.54 P/Share
|
|
Oct 31
2023
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
5,651
-13.92%
|
$2,006,105
$355.92 P/Share
|
|
Oct 17
2023
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
5,651
-12.22%
|
$2,107,823
$373.25 P/Share
|
|
Oct 17
2023
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
243
-5.86%
|
$91,125
$375.0 P/Share
|
|
Oct 16
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
12,962
-36.63%
|
$4,847,788
$374.0 P/Share
|
|
Oct 06
2023
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
242
-5.52%
|
$87,120
$360.0 P/Share
|
|
Oct 05
2023
|
Michel Lagarde Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,132
+50.0%
|
-
|
|
Oct 03
2023
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
5,651
-10.89%
|
$1,949,595
$345.28 P/Share
|
|
Oct 02
2023
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
610
-5.46%
|
$211,060
$346.76 P/Share
|